Why Europe Generic Companies Should Fear Indian Companies (this time). Lessons for Newcomers.
For more than 30 years, European market has been a priority for Indian pharmaceutical generic manufacturers. Aurobindo, Dr Reddys or...
ค้นหา
- 20 ส.ค. 2564
8 common mistakes pharmaceutical companies make when addressing European Markets.
Non-European pharmaceutical companies that choose to enter European markets plead different reasons to do so: access to a developed...
- 20 ส.ค. 2564
Management (specific?) skills to succeed in pharmaceutical emerging markets.
According to the results of the Emergpharma 2018 panel, top pharmaceutical companies still have a lot of work to do in emerging markets....
- 20 ส.ค. 2564
Notes on the German generics and biosimilars market 2016-2018.
German generics market is the biggest in Europe in terms of values and units. It is also one of the most dynamic and with the largest...
- 20 ส.ค. 2564
Parallel trading get 30% of branded products to Big Pharma in German market after patent expiration.
A sub-study from the report “German generics market 2016-2018” recently published by Emergpharma shows interesting facts regarding the...
- 20 ส.ค. 2564
Oncology products will represent more than 20% of the German drug market. Can the system support it?
Preliminary results of the First Report on the German market of oncological medicines 2016-2018 performed by Emergpharma show some...
- 20 ส.ค. 2564
Biosimilars of Rituximab grab 50% market share in top EU markets after less than 2 years.
Mabthera (rituximab) has faced the launch of first biosimilars in EU markets between 2016 and 2018. Some outcomes from Emergpharma's...
- 20 ส.ค. 2564
Biosimilars following same pattern as generics? Neupogen keeps just 6% of EU market after 10 years.
Twelve years after the launch of the first biosimilar in Europe, there are still limited data available on the medium-term impact of the...
- 20 ส.ค. 2564
Anti TNF biosimilars infliximab and etanercept conquer 63% and 44% of the Top 5 EU in under 3 years.
The available data on biosimilars in Europe are still insufficient to carry out a rigorous analysis to show correlations. However, given...
- 20 ส.ค. 2564
Commercial strategies for biosimilars: Any sense to register several brands?
Biosimilars have traditionally been seen by large pharmaceutical companies as a threat to their most profitable products and the priority...
- 20 ส.ค. 2564
8 (avoidable) mistakes made by pharmaceutical companies when entering European markets.
Recently we were hired by a pharmaceutical company with headquarters in an Asian country that had decided to expand to European markets....
- 20 ส.ค. 2564
4 frequent errors healthcare/pharma companies make when entering new markets
Healthcare companies, mostly small and medium-size, are making relevant errors that seriously compromise their chances of success in new...
- 20 ส.ค. 2564
Is it true that biosimilars will increase the use of the molecule? Not always...
Conclusions of a survey on biosimilar adoption in the EU Top 5 A few weeks ago I published an article in Biosimilar Development on the...
- 20 ส.ค. 2564
At least 255 pharmaceuticals playing biosimilars. Rise of the "Pharmerging" middle class.
Preliminary results of the Emergpharma’s “biosimilar 255 tracking January 2020” Emergpharma has just completed the first phase of its...
- 20 ส.ค. 2564
Lessons taken from the coronavirus: redundant models instead of optimized can save us next time.
We are witnessing the collapse of the units of intensive care in hospitals. The coronavirus crisis, that apparently "nobody saw coming"...
- 20 ส.ค. 2564
Pros & Cons of today's best therapeutic option for Covid-19. What to do when we don't have time?
"After reviewing the existing literature on possible therapeutic options; treating patients with severe or critical Covid-19-induced...
- 20 ส.ค. 2564
Biosimilars to increase adoption of biologics in Emerging Markets. Past Evidence for the Future.
In previous articles, I have shown some ideas about the past, present, and future of biosimilars. Once again, I would like to insist on...
- 20 ส.ค. 2564
Tenders and long term sustainability of biosimilars in Europe
As we insist on almost all our articles, biosimilars are not an option, but a need. As commented in our presentation last Thursday at...
- 19 ส.ค. 2564
13 recommendations to succeed when selecting 2nd wave biosimilars.
Risks associated with the decision to develop biosimilars As we have seen in recent years, many companies that have developed or...
- 19 ส.ค. 2564
The Second Wave of Biosimilars. How to find the best ones?
A few days ago, Biopharmalinks (Emergpharma, www.emergpharmalinks.com) finished the first part of its ambitious research on biosimilars...